Home > Efficacy > Metastatic BRAF V600+ Melanoma > Overall Response rate

For first-line targeted therapy in patients with BRAF V600 positive metastatic melanoma

In 2 phase 3 studies, up to 69% of patients experienced complete or partial responses with first-line TAFINLAR + MEKINIST ^1,2

• Greater than 90% of patients achieved disease control with first-line TAFINLAR + MEKINIST^1,2
• The ORR in patients who received TAFINLAR + MEKINIST ranged from 67% to 69% compared with 53% in those who received TAFINLAR monotherapy or vemurafenib monotherapy^1,2
• TAFINLAR + MEKINIST has a low rate of primary resistance^a (6%)^1,2

_{^a Primary resistance is defined as best response to therapy being progressive disease.}
 

In a post hoc analysis across the 3 randomized studies, TAFINLAR + MEKINIST demonstrated high response rates even in patients with elevated LDH levels at baseline³

• Data from the patients who received TAFINLAR + MEKINIST across the 3 randomized studies were pooled³
  • In patients with normal LDH levels at baseline, the ORR was 74%
  • In patients with LDH levels of >1 to ≤2 × ULN at baseline, the ORR was 59%
  • In patients with LDH levels of >2 × ULN at baseline, the ORR was 51%